Medicaid Drug Rebate Program: The Numbers That Decide What Manufacturers Owe

The Medicaid Drug Rebate Program requires participating drug manufacturers to pay rebates on covered outpatient drugs, calculated from reported prices, drug category and Medicaid use. A hidden hospital discount, a service fee deducted in the wrong place or an old drug given a new price history can shrink that bill. If you work in government pricing, contracting or finance, you may know exactly where the reported number parted company with the transaction.

Mylan agreed to a $465 million settlement in 2017 over allegations that it reported EpiPen as a generic despite the absence of a therapeutically equivalent drug. The Justice Department alleged that the company raised EpiPen’s price by approximately 400% between 2010 and 2016 while paying the fixed generic rebate.

Under Medicaid drug rebate law, manufacturers enter rebate agreements as a condition of coverage for their drugs. The manufacturer reports the prices. The state reports the units it paid for. Those inputs determine the rebate owed back to the state. A false input can leave taxpayers paying more for the same medicine.

States also receive supplemental rebates and use formularies and prior authorization to manage drug coverage in their health care programs. These sit alongside the federal rebate obligation. A manufacturer’s commercial deal, its government price report and the state’s pharmacy payment each describe a different part of the same business.

AMP and Best Price Measure Different Transactions

Average manufacturer price, usually called AMP, measures prices paid to the manufacturer through the retail community pharmacy channel. It includes wholesalers buying for that channel and retail community pharmacies buying directly. That boundary matters to anyone deciding which transactions enter the calculation.

Customary prompt-pay discounts to wholesalers and qualifying service fees are excluded from AMP. Payments and rebates involving pharmacy benefit managers, hospitals and other nonretail purchasers generally sit outside it. Certain drugs not usually dispensed through retail community pharmacies follow different rules. Other discounts and payments passed through to retail community pharmacies belong in the calculation.

Best Price looks for the lowest qualifying price available from the manufacturer during the rebate period. Cash discounts, volume discounts, rebates and purchase-dependent free goods count. Special packaging or a private label does not remove a qualifying price from consideration.

Best Price also has its own exclusions, including qualifying federal purchases, 340B purchases and prices negotiated by Medicare Part D plans. The separate Medicare-negotiated maximum fair price enters Best Price for selected drugs. A pricing team has to identify the purchaser, the program and the concession before deciding where a transaction belongs.

Public list prices can obscure those differences. The USC Schaeffer Center’s 2020 paper, The Association Between Drug Rebates and List Prices, found that increases in estimated rebates were associated with increases in list prices. The paper draws a conclusion that reaches beyond government payments:

For a government-pricing employee, the question is which payment went to which buyer, and how it entered AMP or Best Price.

How the Medicaid Rebate Is Calculated

The Medicaid rebate calculation starts with a basic rebate per unit, adds any inflation rebate and multiplies the result by the state’s eligible units for that dosage form and strength. The Medicaid drug rebate regulation separates the basic calculation by drug category:

• Most single-source and innovator multiple-source drugs: the greater of 23.1% of AMP or AMP minus Best Price.
• Clotting factors and drugs approved exclusively for pediatric indications: the greater of 17.1% of AMP or AMP minus Best Price.
• Noninnovator multiple-source drugs: 13% of AMP, without a Best Price comparison.

The inflation component compares the current quarter’s AMP with the drug’s base-date AMP adjusted for inflation. When current AMP exceeds that inflation-adjusted baseline, the excess adds to the rebate. Both innovator and noninnovator drugs can owe this additional amount. Generic inflation rebates began in 2017.

Applying today’s formula to an older report can miss the obligation that actually existed then.

Medicaid Rebate Inflation Cap Removal: Why Reporting Errors Matter

For rebate periods beginning January 1, 2024, the total rebate can exceed the drug’s AMP. That makes reporting errors in AMP and the inflation baseline more consequential. The former 100% cap applied to brand-drug rebates during 2010 through 2023 and noninnovator rebates during 2015 through 2023.

For older brand drugs, the inflation comparison reaches back to the third quarter of 1990. Later drugs generally use the first full calendar quarter after initial marketing. Substituting a later, higher base price removes earlier price increases from the comparison. The manufacturer can then appear to owe less without changing the price charged today.

A qualifying line extension of an oral solid drug can still owe rebates tied to the original product’s price increases. Under the formula effective January 1, 2022, the larger of its own rebate or the alternative linked to the original drug governs when the manufacturers are the same or have the required corporate relationship.

Drug Category Can Change the Whole Bill

Drug category determines which basic formula applies. The reported categories distinguish single-source, innovator multiple-source and noninnovator multiple-source drugs. The approval pathway matters to that classification, alongside the product information the manufacturer certifies.

During the EpiPen conduct period, generic drugs did not carry the inflation rebate they do today. The alleged classification choice therefore removed the inflation component as well as lowering the basic rate. A competitor manufacturer brought the whistleblower case.

The problem extended beyond that case. In its December 2017 review, the Department of Health and Human Services’ inspector general estimated $1.3 billion in potentially lost rebates for the ten potentially misclassified drugs with the highest Medicaid reimbursement in 2016, covering rebates from 2012 through 2016. Medicaid data listed them as noninnovator drugs. Food and Drug Administration data listed them as innovator drugs.

Congress added misclassification correction and recovery powers in 2019. The current regulation requires repayment of the difference between the rebate paid and the rebate owed under the correct category, multiplied by the units in each affected period.

The Reporting Calendar and the Assumptions Behind It

Manufacturers report quarterly AMP and Best Price within 30 days after the quarter closes. Quarterly AMP sets the rebate. Monthly AMP serves a separate pharmacy-payment benchmark.

A chief executive, chief financial officer, someone with equivalent authority or a directly delegated individual certifies the reports. The price data are confidential. The manufacturer has an express right to audit state utilization, while the state has no reciprocal right to audit the manufacturer’s price calculations.

That makes the internal calculation file unusually important. The inspector general’s September 2019 report on reasonable assumptions found that the Centers for Medicare & Medicaid Services did not assess most manufacturer assumptions. The agency had historically instructed manufacturers not to submit them routinely. Manufacturers must retain records of calculation assumptions for ten years.

The assumption can explain why a service payment was deducted, why a customer was excluded or why a particular base date was used. A certification shows the number sent to the agency. The assumption, transaction records and internal communications can show how the company reached it and who understood the consequence.

Managed Care and 340B Meet at the Same Unit

Federal rebates reach covered outpatient drugs supplied through Medicaid managed care as well as fee-for-service Medicaid. The Affordable Care Act extended the rebate obligation to managed care in 2010. The current regulation preserves an exception for qualifying managed-care drugs discounted through 340B.

The duplicate-discount question is whether the same unit received a 340B discount and also generated a Medicaid rebate. The dispensing record, the covered entity’s purchase and the state’s utilization record have to identify the same drug and payment path. Enrollment identifies the patient’s coverage. The purchase record identifies the discount.

Oversight has struggled with that distinction. In a January 2020 report, the Government Accountability Office found that the Health Resources and Services Administration assessed potential duplicate discounts in fee-for-service Medicaid but did not fully assess managed-care claims. The report also found that the agency did not require covered entities to address identified managed-care duplicate discounts and work with manufacturers to repay them. The missing connection was between the discount on the purchase and the rebate on the claim.

The same pricing data also affect what safety-net providers pay. The 340B ceiling price generally uses the preceding quarter’s AMP minus the Medicaid unit rebate amount. A concealed qualifying discount that leaves Best Price too high can shrink the Medicaid rebate and raise that ceiling. In the Aventis private-label case, the government alleged both underpaid Medicaid rebates and overcharges to Public Health Service entities. One omitted price could affect both programs.

Medicaid Rebate Calculation: Contract Label Versus Payment

The payment behind a contract’s label can change the Medicaid rebate calculation. What did the customer receive, what did the manufacturer retain, and where did the calculation put that value? The cases show how an apparently small reporting choice can change the obligation across many sales.

Hospital Discounts That Followed the Patient Home

Wyeth and Pfizer agreed to a $784.6 million settlement in 2016 over allegations that Wyeth excluded bundled discounts on oral and intravenous Protonix from Best Price. According to the government, the hospital discount served a longer commercial purpose: patients discharged on oral Protonix were likely to remain on it while Medicaid and other payers paid nearly full price.

The government alleged that Wyeth hid the bundled discounts and underpaid rebates from 2001 through 2006. A discount tied to purchases of several products has to be allocated across the products in the bundle. Looking at one invoice without the agreement can leave out the price concession that earned the sale.

An Old Drug With a New Starting Price

Mallinckrodt’s 2022 settlement assigned approximately $234.7 million to the Acthar rebate allegations. The company admitted that Acthar was approved and marketed before 1990 and was not a new drug in 2013. It agreed to correct the base-date AMP. The government alleged that treating it as new removed earlier price increases from the inflation-rebate calculation.

The whistleblower’s amended complaint describes what happened inside the finance function after the Centers for Medicare & Medicaid Services questioned the calculation:

That allegation puts the calculation and the response to it in the same room. According to the whistleblower, the supervisor’s response to the bill was to limit who could discuss it.

Nostrum supplies a related product-history comparison. In its 2023 Nitro OS settlement, the company admitted that the relaunched drug retained its active ingredients, dosage form and strength. The government alleged unpaid inflation rebates after Nostrum characterized the product as a reformulation. The manufacturing and approval history mattered alongside the new price.

Wholesaler Fees and Money Coming Back

Bristol-Myers Squibb agreed to a $75 million settlement in 2021 over allegations involving two sides of its wholesaler arrangements. The company allegedly reduced AMP improperly for service fees paid to wholesalers and excluded additional value received under price-appreciation provisions.

A wholesaler holding inventory can benefit when the manufacturer’s price rises. A price-appreciation provision returns some of that value to the manufacturer. The government’s allegation was that this money belonged in AMP. The fee going out and the value coming back both mattered to the reported price.

For a service fee to qualify for exclusion, it must pay fair market value for an itemized service actually performed for the manufacturer, which the manufacturer would otherwise perform or buy, and it must not pass through to the recipient’s customer. Calling a payment a service fee does not answer those questions.

What Triggers a Medicaid Fraud Investigation?

A whistleblower complaint can expose a Medicaid rebate shortfall hidden in government pricing reports. In the cases above, whistleblowers identified concealed discounts, incorrect product histories and payment treatments that reduced what manufacturers owed. A useful starting point is the connection between the commercial transaction and the certified government report. We examine that connection with you, including who chose the treatment and what happened when someone questioned it.

The contract explains the bargain. Invoices, credits and payment records show how it operated. Category and base-date histories explain which formula the company used. Calculation files, certifications and state rebate invoices connect those choices to the amount paid.

Is It Hard to Prove Medicaid Fraud?

It takes connecting pricing records most people never see, and that is work we do with you. Our work with you brings the contracts, calculations and internal explanations together so that whistleblower lawyers experienced in drug pricing can pursue the case. A whistleblower case under the False Claims Act, also called a qui tam case, can pay 15% to 30% of what the government recovers.

When You Know Why the Rebate Came Out Lower

If you work in pricing, market access, finance or compliance and know which decision reduced the Medicaid rebate, speak with our whistleblower experts about the calculation behind it. We build the case around the healthcare transactions and pricing decisions you understand, and bring in pharmaceutical fraud whistleblower lawyers who know government price reporting. We stay with you from that first conversation through the case.